UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000026986 |
|---|---|
| Receipt number | R000030940 |
| Scientific Title | Phase 2 trial of utility and safety for bevacizumab in combination with adjuvant chemotherapy in cervical cancer |
| Date of disclosure of the study information | 2017/05/01 |
| Last modified on | 2017/04/13 14:56:11 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase 2 trial of utility and safety for bevacizumab in combination with adjuvant chemotherapy in cervical cancer
Acronym
Trial of adjuvant chemotherapy with bevacizumab in cervical cancer
Scientific Title
Phase 2 trial of utility and safety for bevacizumab in combination with adjuvant chemotherapy in cervical cancer
Scientific Title:Acronym
Trial of adjuvant chemotherapy with bevacizumab in cervical cancer
Region
| Japan |
Condition
Condition
Cervical cancer
Classification by specialty
| Obstetrics and Gynecology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Safety and efficacy of bevacizumab combination with adjuvant chemotherapy
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Disease-free survival
Key secondary outcomes
Side effect
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Self control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
paclitaxel(175mg/m2) + carboplatin(AUC5) + bevacizumab(15mg/kg) for 6 months
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Female
Key inclusion criteria
1)Diagnosis with cervical cancer.
2)PS 0 or 1
3)Consent from the patient.
4)Pathological examination recognized risk of recurrence.
Key exclusion criteria
1)Patients have severe fever.
2)Patients have a hystory acute myocardial infarction.
3)Patients have ileus symptom.
4)Patients have poor control of DM and HT and VTE.
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Masahide Ohmichi |
Organization
Osaka medical college
Division name
Obstetrics and gynecology
Zip code
Address
2-7, Daigaku-machi, Takatuki-shi, Osaka, 569-8686, Japan
TEL
072-863-1221
gyn140@osaka-med.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Keisuke Ashihara |
Organization
Osaka medical college
Division name
Obstetrics and gynecology
Zip code
Address
2-7, Daigaku-machi, Takatuki-shi, Osaka, 569-8686, Japan
TEL
072-863-1221
Homepage URL
gyn140@osaka-med.ac.jp
Sponsor or person
Institute
Osaka medical college
Institute
Department
Personal name
Funding Source
Organization
Osaka medical college
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 05 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2017 | Year | 04 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2017 | Year | 04 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2017 | Year | 04 | Month | 13 | Day |
Last modified on
| 2017 | Year | 04 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030940
